Manufacturing Giant Jabil Breaks into Contract Drug Development with Strategic Acquisition
.jpg)
Jabil, a versatile multi-industry manufacturer with an established foothold in healthcare, is making a strategic leap into the contract development and manufacturing organization (CDMO) market. The company has acquired Pharmaceutics International, a Maryland-based pharmaceutical services firm, in a significant move that expands its capabilities in the biopharma sector.
The recently completed transaction provides Jabil with immediate and robust capabilities in critical pharmaceutical manufacturing services. These include advanced aseptic filling, sophisticated freeze-drying techniques, and comprehensive oral solid dose production across multiple stages of product development. By bringing Pharmaceutics International under its corporate umbrella, Jabil is signaling a bold commitment to becoming a more prominent player in the pharmaceutical contract manufacturing landscape.
While the financial details of the acquisition remain confidential, the strategic implications are clear: Jabil is positioning itself to offer more integrated and comprehensive solutions to pharmaceutical and biotechnology clients seeking end-to-end manufacturing support.